Can valacyclovir (Valtrex) be safely used during pregnancy, and what are the recommended dosing regimens for primary and recurrent herpes simplex infections?

Valtrex in Pregnancy

Valacyclovir (Valtrex) can be safely used during pregnancy for treatment of herpes simplex virus infections, with registry data showing no increased risk of major birth defects compared to the general population. 1

Safety Profile

The FDA drug label and pregnancy registries provide reassuring data on valacyclovir safety:

• Acyclovir Pregnancy Registry (1,246 exposures): Major birth defects occurred in 3.2% with first-trimester exposure and 2.6% with any trimester exposure—rates comparable to the general population 1
• Valacyclovir Pregnancy Registry (111 exposures): Major birth defects occurred in 4.5% with first-trimester exposure and 3.9% with any trimester exposure 1
• A large Danish cohort study of 837,795 infants found no association between first-trimester antiviral exposure and major birth defects (adjusted POR 0.89; 95% CI: 0.65-1.22) 2

Important caveat: One case-control study suggested a possible association with gastroschisis, but this had significant methodological limitations including recall bias and demographic confounders 3. Acyclovir remains FDA pregnancy category B.

Treatment Recommendations by Clinical Scenario

First Episode Genital Herpes During Pregnancy

Treat immediately with oral antivirals 4, 5:

• Acyclovir 200 mg orally 5 times daily for 5-10 days, OR
• Valacyclovir 1000 mg orally twice daily for 5-10 days

The CDC guidelines specifically state that "the first clinical episode of genital herpes during pregnancy may be treated with oral acyclovir" 4. This is critical because first-episode infections near delivery carry a 30-50% risk of neonatal transmission 4.

Recurrent Genital Herpes During Pregnancy

Treatment is optional for symptomatic episodes 6, 7:

• Acyclovir 200 mg orally 5 times daily for 5-10 days, OR
• Valacyclovir 500 mg orally twice daily for 5-10 days

The evidence for efficacy on symptom duration is limited, but treatment can be offered based on symptom severity 6, 7.

Suppressive Therapy Starting at 36 Weeks

Offer suppressive therapy from 36 weeks until delivery for women with:

• Any episode of genital herpes during the current pregnancy (first episode or recurrent) 3, 5, 7

Dosing regimens 3, 5, 7:

• Acyclovir 400 mg orally 3 times daily, OR
• Valacyclovir 500 mg orally twice daily

This approach reduces viral shedding, recurrences at term, and cesarean delivery rates 3. However, the CDC guidelines note that "routine administration of acyclovir to pregnant women who have a history of recurrent genital herpes is not recommended at this time" if there have been no episodes during the current pregnancy 4.

Life-Threatening Maternal HSV Infection

Use IV acyclovir 5 mg/kg every 8 hours for disseminated infection, encephalitis, pneumonitis, or hepatitis 4. Maternal mortality risk justifies aggressive treatment.

Delivery Management

Cesarean Section Indications

Perform cesarean delivery if 5:

• Suspected first episode genital herpes at onset of labor
• First episode genital herpes less than 6 weeks before delivery
• Premature rupture of membranes at term with active lesions

Recurrent Herpes at Labor

Decision algorithm 6:

• Intact membranes → Consider cesarean delivery (neonatal transmission risk ~1%)
• Prolonged rupture of membranes at term → Consider vaginal delivery (cesarean benefit diminishes)
• Prematurity or HIV co-infection → Favor cesarean delivery

The risk of neonatal transmission with recurrent herpes at delivery is only 1% compared to 30-50% with primary infection 4.

Critical Neonatal Transmission Context

Understanding transmission risk is essential for counseling:

• Primary infection near delivery: 30-50% transmission risk 4
• Recurrent infection at delivery: 1-3% transmission risk 4
• First-half pregnancy acquisition: 3% transmission risk 4

Most mothers of infants with neonatal herpes lack a history of clinically evident genital herpes 4, emphasizing the importance of preventing acquisition during late pregnancy through counseling about avoiding unprotected sexual contact if partner status is unknown.

Reporting Requirement

Report all valacyclovir or acyclovir exposures during pregnancy to the manufacturer's registry, though the original CDC registry phone number (800-722-9292, ext. 38465) from the 1998 guidelines may no longer be active 4.

Breastfeeding

Valacyclovir is compatible with breastfeeding 1. Acyclovir (the active metabolite) appears in breast milk at levels that would provide a breastfed infant approximately 0.6 mg/kg/day—well below therapeutic dosing. No adverse effects on breastfed infants have been reported.